Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...
So welcome, everyone. Thank you for joining us this afternoon. I'm Dave Barton. I head up, U.S. and Canada Telecom and Communications Infrastructure Research for Bank of America. Thank you for joining ...